Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T19:33:01.431Z Has data issue: false hasContentIssue false
  • English
  • Français

Acetylcholinesterase inhibitor donepezil in the treatment of cognitive deficit in schizophrenia. Subanalysis of the active branch from Czech extended double blind study

Published online by Cambridge University Press:  16 April 2020

M. Pérez ,
I. Tůma ,
O. Pytela ,
E. Kadlecová ,
M. Zemanová  and
Z. Lenderová
M. Pérez*
Affiliation:
Department of Psychiatry, Hospital Havirov, Charles University, Prague, Faculty of Medicine, Hradec Kralove, Czech Republic
I. Tůma
Affiliation:
Department of Psychiatry, Hospital Havirov, Charles University, Prague, Faculty of Medicine, Hradec Kralove, Czech Republic
O. Pytela
Affiliation:
Department of Psychiatry, Teaching Hospital Hradec Králové, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic
E. Kadlecová
Affiliation:
University of Pardubice, Faculty of Chemical Technology, Czech Republic
M. Zemanová
Affiliation:
Department of Psychiatry Pisek, Czech Republic
Z. Lenderová
Affiliation:
State Psychiatric Hospital Havlickuv Brod, Czech Republic
*
*Corresponding author. Na Dolním Poli, 12, Opava, 746 01, Czech Republic. E-mail address: prim.psychiatrie@nsphav.cz (M. Pérez).
Get access

Abstract

The article mentions the conclusions of most evidential works investigating donepezil in the treatment of cognitive deficit in schizophrenia. It focuses on an analysis of a sub-group of 20 patients receiving treatment of the donepezil in an extended Czech double-blind placebo controlled study.

Keywords

SchizophreniaCognitive deficitAcetylcholinesterase InhibitorsAChEiDonepezil
Type
Short communication
Information
European Psychiatry , Volume 21 , Issue 8 , December 2006 , pp. 548 - 550
Copyright
Copyright © Elsevier Masson SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Friedman, J.I., Adler, D.N., Howanitz, E., Harvey, P.D., Brenner, G., Temporini, H.et al.Double-blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia Biol. Psych. 2002; 51:349–357.CrossRefGoogle ScholarPubMed
Moller, H.J.Risperidone: a review Expert Opin. Pharmacother. 6(5)2005 803–818.CrossRefGoogle ScholarPubMed
Nahas, Z., George, M.S., Horner, M.D., Markowitz, J.S., Li, X., Owens, S.D.et al.Augmenting atypical anti-psychotics with a cognitive enhancement (donepezil) improves local brain activity in schizophrenia patients: pilot double-blind placebo controlled BOLD fMRI trial Neurocase 9(3)2003 274–282.CrossRefGoogle Scholar
Pérez, M.Cholinergic neurotransmission and cognitive functions in relation to schizophrenia Czech Psychiatrist 2004; 8:489–490.Google Scholar
Risch, S.G., McGurk, S., Horner, M.D., Nahas, Z., Owens, S.D., Molloy, M.et al.A double-blind placebo controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates Neurocase 2001; 7:105–110.CrossRefGoogle Scholar
Tugal, O., Yazici, K.M., Yacolu, A.E.A double-blind, placebo-controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia Int. J. Neuropsychopharmacol. 7(2)2004 117–123.Google Scholar
Tůma, I., Pérez, M., Lenderová, Z., Zemanová, M., Kadlecová, E.Treatment of cognitive dysfunction in schizophrenia by donepezil: double-blind, placebo controlled trial Psychiatry 8(2)2004 93–99.Google Scholar
Submit a response

Comments

No Comments have been published for this article.